Use of Incretin Therapy in the Treatment of Type 2 Diabetes Mellitus
Authors:
- Michelle P. ZappasMZMichelle P. Zappas
- Meredith GentesMGMeredith Gentes
- Benita Walton-MossBWBenita Walton-Moss
- 1 June 2017
- journal article
- Published by Elsevier in The Journal for Nurse Practitioners
- Vol. 13 (6) , 418-424
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARYEndocrine Practice, 2016
- GLP‐1 receptor agonists vs. DPP‐4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?International Journal Of Clinical Practice, 2014
- Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor AgonistsClinical Diabetes, 2014
- Practical Use of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Primary CareClinical Diabetes, 2013
- Hypoglycemia: The neglected complicationIndian Journal of Endocrinology and Metabolism, 2013
- Putting medications where they belong: Practical advice for managing type 2 diabetes in clinical practiceJournal of the American Association of Nurse Practitioners, 2013
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label studyThe Lancet, 2013
- DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trialsDiabetes & Metabolism, 2012
- Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial EvidenceClinical Diabetes, 2012
- DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2011